bioMerieux SA 2024 AR2
The report highlights bioMérieux's achievements in 2024, focusing on its fight against antimicrobial resistance and its GO•28 strategic plan. The company achieved 10.3% sales growth, reaching ’3,980 million, and reinvested 12.3% of sales into R&D. On the environmental front, bioMérieux reduced its greenhouse gas emissions by 13% compared to 2019, aligning with its SBTi-validated target of a 50% reduction by 2030. Additionally, the company advanced its eco-design initiatives, with 89% of its kits now featuring eco-designed packaging, and continued its commitment to diversity and employee engagement.
Company: bioMerieux SA
Sector: Health Care
Country: France
Year: 2024
Type: AR2
Pages: 29
bioMerieux SA
Annual Report
The report highlights bioMérieux's achievements in 2024, focusing on its fight against antimicrobial resistance and its GO•28 strategic plan. The company achieved 10.3% sales growth, reaching ’3,980 million, and reinvested 12.3% of sales into R&D. On the environmental front, bioMérieux reduced its greenhouse gas emissions by 13% compared to 2019, aligning with its SBTi-validated target of a 50% reduction by 2030. Additionally, the company advanced its eco-design initiatives, with 89% of its kits now featuring eco-designed packaging, and continued its commitment to diversity and employee engagement.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Women on Board
Women in Management
Employees